SpringerLink - Journal Article

Abstract The extracellular matrix molecule tenascin-C is highly expressed during embryonic development, tissue repair and in pathological situations such as chronic inflammation and cancer. Tenascin-C interacts with several other extracellular matrix molecules and cell-surface receptors, thus affecting tissue architecture, tissue resilience and cell responses. Tenascin-C modulates cell migration, proliferation and cellular signaling through induction of pro-inflammatory cytokines and oncogenic signaling molecules amongst other mechanisms. Given the causal role of inflammation in cancer progression, common mechanisms might be controlled by tenascin-C during both events. Drugs targeting the expression or function of tenascin-C or the tenascin-C protein itself are currently being developed and some drugs have already reached advanced clinical trials. This generates hope that increased knowledge about tenascin-C will further improve management of diseases with high tenascin-C expression such as chronic inflammation, heart failure, artheriosclerosis and cancer.

References

Adams M, Jones JL, Walker RA, Pringle JH, Bell SC (2002) Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 62:3289–3297

Aicher A, Kollet O, Heeschen C, Liebner S, Urbich C, Ihling C, Orlandi A, Lapidot T, Zeiher AM, Dimmeler S (2008) The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 103:796–803

Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, Bigner DD, Zalutsky MR (2005) Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 46:1042–1051

Alexopoulou AN, Multhaupt HA, Couchman JR (2007) Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 39:505–528

Amin K, Ekberg-Jansson A, Lofdahl CG, Venge P (2003) Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study. Thorax 58:135–142

Amin K, Ludviksdottir D, Janson C, Nettelbladt O, Bjornsson E, Roomans GM, Boman G, Seveus L, Venge P (2000) Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma BHR Group. Am J Respir Crit Care Med 162:2295–2301

Aukhil I, Joshi P, Yan Y, Erickson HP (1993) Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. J Biol Chem. 268:2542–2553

Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 7:211–217

Ballard VL, Sharma A, Duignan I, Holm JM, Chin A, Choi R, Hajjar KA, Wong SC, Edelberg JM (2006) Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. Faseb J. 20:717–719

Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C, Kirchner T, Jung A (2005) beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene. 24:8200–8204

Bell SC, Pringle JH, Taylor DJ, Malak TM (1999) Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes. Mol Hum Reprod. 5:1066–1076

Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52

Betz P, Nerlich A, Tubel J, Penning R, Eisenmenger W (1993) Localization of tenascin in human skin wounds-an immunohistochemical study. Int J Legal Med 105:325–328

Bissell MJ, Labarge MA (2005) Context tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 7:17–23

Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer. 1:46–54

Borsi L, Allemanni G, Gaggero B, Zardi L (1996) Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells. Int J Cancer 66:632–635

Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querze G, Zardi L (1994) Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhes Commun 1:307–317

Boyd NL, Martin S, Chavez A, Gunasekara A, Salleh O, Melnichouk M, Yaffe C, Friedenreich S, Minkin, Bronskill M (2009) Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. Lancet Oncol 10:569–580

Busse WW, Lemanske RF Jr (2001) Asthma. N Engl J Med. 344:350–362

Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, Huh JI, Sharp R, Qiu TH, Anver MR, Merlino G, Dickson RB, Johnson MD, Green JE (2008) Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene 27:5373–5386

Canfield AE, Schor AM (1995) Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci. 108(Pt 2):797–809

Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389–395

Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L (1999) Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 154:1345–1352

Castellon R, Caballero S, Hamdi HK, Atilano SR, Aoki AM, Tarnuzzer RW, Kenney MC, Grant MB, Ljubimov AV (2002) Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci 43:2758–2766

Cella N, Chiquet-Ehrismann R, Hynes NE (2000) Lactogenic hormones and tenascin-C regulate C/EBPalpha and beta in mammary epithelial cells. J Cell Biochem. 76:394–403

Chiquet M, Fambrough DM (1984) Chick myotendinous antigen I. A monoclonal antibody as a marker for tendon and muscle morphogenesis. J Cell Biol. 98:1926–1936

Chiquet M, Gelman L, Lutz R, Maier S (2009) From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim Biophys Acta 1793:911–920

Chiquet-Ehrismann R (2004) Tenascins. Int J Biochem Cell Biol 36:986–990

Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol. 200:488–499

Chiquet-Ehrismann R, Hagios C, Matsumoto K (1994) The tenascin gene family. Perspect Dev Neurobiol 2:3–7

Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T (1986) Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47:131–139

Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, Chiquet M (1991) Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul. 2:927–938

Chung CY, Erickson HP (1994) Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol. 126:539–548

Chung CY, Erickson HP (1997) Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. J Cell Sci. 110:1413–1419

Chung CY, Murphy-Ullrich JE, Erickson HP (1996) Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 7:883–892

Chung CY, Zardi L, Erickson HP (1995) Binding of tenascin-C to soluble fibronectin and matrix fibrils. J Biol Chem. 270:29012–29017

Clark RA (1993) Biology of dermal wound repair. Dermatol Clin 11:647–666

Clark RA, Erickson HP, Springer TA (1997) Tenascin supports lymphocyte rolling. J Cell Biol. 137:755–765

Cohen ED, Ihida-Stansbury K, Lu MM, Panettieri RA, Jones PL, Morrisey EE (2009) Wnt signaling regulates smooth muscle precursor development in the mouse lung via a tenascin C/PDGFR pathway. J Clin Invest. 119:2538–2549

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867

Cowan KN, Jones PL, Rabinovitch M (2000) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 105:21–34

Crossin KL (1991) Cytotactin binding: inhibition of stimulated proliferation and intracellular alkalinization in fibroblasts. Proc Natl Acad Sci U S A. 88:11403–11407

Day JM, Olin AI, Murdoch AD, Canfield A, Sasaki T, Timpl R, Hardingham TE, Aspberg A (2004) Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J Biol Chem. 279:12511–12518

De Wever O, Nguyen QD, Van Hoorde L, Bracke M, Bruyneel E, Gespach C, Mareel M (2004) Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. Faseb J. 18:1016–1018

Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, Orend G, Chiquet-Ehrismann R (2007) Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Res 67:9169–9179

Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, Tornillo L, Terracciano L, Chiquet-Ehrismann R, Ruegg C, Seelentag W (2008) Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer 122:2454–2461

Denda S, Müller U, Crossin KL, Erickson HP, Reichardt LF (1998) Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin alpha 8 beta 1 receptor interactions with tenascin: murine alpha 8 beta 1 binds to the RGD site in tenascin-C fragments, but not to native tenascin-C. Biochemistry 37:5464–5474

Derr LB, Chiquet-Ehrismann R, Gandour-Edwards R, Spence J, Tucker RP (1997) The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation. 62:71–82

DiMeo TA, Anderson K, Phadke P, Feng C, Perou CM, Naber S, Kuperwasser C (2009) A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 69:5364–5373

Dobrovolskaia MA, Kozlov SV (2005) Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets. 5:325–344

Drumea-Mirancea M, Wessels JT, Muller CA, Essl M, Eble JA, Tolosa E, Koch M, Reinhardt DP, Sixt M, Sorokin L, Stierhof YD, Schwarz H, Klein G (2006) Characterization of a conduit system containing laminin-5 in the human thymus: a potential transport system for small molecules. J Cell Sci. 119:1396–1405

Dueck M, Riedl S, Hinz U, Tandara A, Moller P, Herfarth C, Faissner A (1999) Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer 82:477–483

El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, Imanaka-Yoshida K (2007) Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol. 211:86–94

End P, Panayotou G, Entwistle A, Waterfield MD, Chiquet M (1992) Tenascin: a modulator of cell growth. Eur J Biochem 209:1041–1051

Faissner A (1997) The tenascin gene family in axon growth and guidance. Cell Tissue Res 290:331–341

Faissner A, Kruse J, Kuhn K, Schachner M (1990) Binding of the J1 adhesion molecules to extracellular matrix constituents. J Neurochem. 54:1004–1015

Fassler R, Sasaki T, Timpl R, Chu ML, Werner S (1996) Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and glucocorticoid-treated mice. Exp Cell Res 222:111–116

Filsell W, Rudman S, Jenkins G, Green MR (1999) Coordinate upregulation of tenascin C expression with degree of photodamage in human skin. Br J Dermatol 140:592–599

Fischer D, Chiquet-Ehrismann R, Bernasconi C, Chiquet M (1995) A single heparin binding region within the fibrinogen-like domain is functional in chick tenascin-C. J Biol Chem. 270:3378–3384

Fischer D, Tucker RP, Chiquet-Ehrismann R, Adams JC (1997) Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Mol Biol Cell 8:2055–2075

Fischer JW (2007) Tenascin-C: a key molecule in graft stenosis. Cardiovasc Res 74:335–336

Fluck M, Mund SI, Schittny JC, Klossner S, Durieux AC, Giraud MN (2008) Mechano-regulated tenascin-C orchestrates muscle repair. Proc Natl Acad Sci U S A. 105:13662–13667

Forsberg E, Hirsch E, Frohlich L, Meyer M, Ekblom P, Aszodi A, Werner S, Fassler R (1996) Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci U S A. 93:6594–6599

Fujinaga K, Onoda K, Yamamoto K, Imanaka-Yoshida K, Takao M, Shimono T, Shimpo H, Yoshida T, Yada I (2004) Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg. 128:357–363

Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E (2007) Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9:1392–1400

Geboes K, El-Zine MY, Dalle I, El-Haddad S, Rutgeerts P, Van Eyken P (2001) Tenascin and strictures in inflammatory bowel disease: an immunohistochemical study. Int J Surg Pathol. 9:281–286

Geffrotin C, Tricaud Y, Crechet F, Castelli M, Lefaix JL, Vaiman M (1998) Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation. Radiat Res 149:472–481

Gerritsen MJ, Elbers ME, de Jong EM, van de Kerkhof PC (1997) Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin. J Dermatol Sci. 14:179–188

Ghatnekar A, Trojanowska M (2008) GATA-6 is a novel transcriptional repressor of the human Tenascin-C gene expression in fibroblasts. Biochim Biophys Acta 1779:145–151

Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L (1995) Human tenascin gene. Structure of the 5′-region, identification, and characterization of the transcription regulatory sequences. J Biol Chem 270:3429–3434

Giese A, Loo MA, Norman SA, Treasurywala S, Berens ME (1996) Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins. J Cell Sci. 109(Pt 8):2161–2168

Gindre D, Peyrol S, Raccurt M, Sommer P, Loire R, Grimaud JA, Cordier JF (1995) Fibrosing vasculitis in Wegener’s granulomatosis: ultrastructural and immunohistochemical analysis of the vascular lesions. Virchows Arch 427:385–393

Goodger SJ, Robinson CJ, Murphy KJ, Gasiunas N, Harmer NJ, Blundell TL, Pye DA, Gallagher JT (2008) Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem. 283:13001–13008

Gordon S (2002) Pattern recognition receptors: doubling up for the innate immune response. Cell 111:927–930

Gotz M, Bolz J, Joester A, Faissner A (1997) Tenascin-C synthesis and influence on axonal growth during rat cortical development. Eur J NeuroSci 9:496–506

Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL (2009) Tumor-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11:R24

Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D, Dong Z (2002) Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101:415–422

Hauzenberger D, Olivier P, Gundersen D, Ruegg C (1999) Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol 29:1435–1447

Hedin U, Holm J, Hansson GK (1991) Induction of tenascin in rat arterial injury Relationship to altered smooth muscle cell phenotype. Am J Pathol 139:649–656

Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 14:5555–5564

Hemesath TJ, Marton LS, Stefansson K (1994) Inhibition of T cell activation by the extracellular matrix protein tenascin. J Immunol. 152:5199–5207

Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 3:411–421

Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH (2002) Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98:362–369

Herrmann T, Grosse-Hovest L, Otz T, Krammer PH, Rammensee HG, Jung G (2008) Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 68:1221–1227

Hibino S, Kato K, Kudoh S, Yagita H, Okumura K (1998) Tenascin suppresses CD3-mediated T cell activation. Biochem Biophys Res Commun 250:119–124

Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG (2006) Tumor targeting by an aptamer. J Nucl Med. 47:668–678

Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G (2001) Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61:8586–8594

Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer. 3:276–285

Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y (1994) Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 352:216–218

Ingber DE (2002) Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 91:877–887

Ingham KC, Brew SA, Erickson HP (2004) Localization of a cryptic binding site for tenascin on fibronectin. J Biol Chem. 279:28132–28135

Ishii K, Imanaka-Yoshida K, Yoshida T, Sugimura Y (2008) Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Dev Biol 324:310–319

Ishikawa F, Nose K, Shibanuma M (2008) Downregulation of hepatocyte nuclear factor-4alpha and its role in regulation of gene expression by TGF-beta in mammary epithelial cells. Exp Cell Res 314:2131–2140

Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, Pestell RG, Scherer PE (2003) Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene. 22:6408–6423

Iyer AK, Tran KT, Borysenko CW, Cascio M, Camacho CJ, Blair HC, Bahar I, Wells A (2007) Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity. J Cell Physiol. 211:748–758

Iyer AK, Tran KT, Griffith L, Wells A (2008) Cell surface restriction of EGFR by a tenascin cytotactin-encoded EGF-like repeat is preferential for motility-related signaling. J Cell Physiol. 214:504–512

Jallo GI, Friedlander DR, Kelly PJ, Wisoff JH, Grumet M, Zagzag D (1997) Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis. Neurosurgery. 41:1052–1059

Joester A, Faissner A (2001) The structure and function of tenascins in the nervous system. Matrix Biol 20:13–22

Jones FS, Hoffman S, Cunningham BA, Edelman GM (1989) A detailed structural model of cytotactin: protein homologies, alternative RNA splicing, and binding regions. Proc Natl Acad Sci U S A. 86:1905–1909

Jones PL, Boudreau N, Myers CA, Erickson HP, Bissell MJ (1995) Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells Localization of active regions using recombinant tenascin fragments. J Cell Sci. 108(Pt 2):519–527

Jones PL, Crack J, Rabinovitch M (1997) Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol. 139:279–293

Jones PL, Jones FS (2000) Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 19:581–596

Julian J, Chiquet-Ehrismann R, Erickson HP, Carson DD (1994) Tenascin is induced at implantation sites in the mouse uterus and interferes with epithelial cell adhesion. Development. 120:661–671

Kaariainen E, Nummela P, Soikkeli J, Yin M, Lukk M, Jahkola T, Virolainen S, Ora A, Ukkonen E, Saksela O, Holtta E (2006) Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol. 210:181–191

Kaarteenaho-Wiik R, Lakari E, Soini Y, Pollanen R, Kinnula VL, Paakko P (2000) Tenascin expression and distribution in pleural inflammatory and fibrotic diseases. J Histochem Cytochem. 48:1257–1268

Kaarteenaho-Wiik R, Mertaniemi P, Sajanti E, Soini Y, Paakko P (1998) Tenascin is increased in epithelial lining fluid in fibrotic lung disorders. Lung 176:371–380

Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T (2003) Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 105:53–60

Kanayama M, Kurotaki D, Morimoto J, Asano T, Matsui Y, Nakayama Y, Saito Y, Ito K, Kimura C, Iwasaki N, Suzuki K, Harada T, Li HM, Uehara J, Miyazaki T, Minami A, Kon S, Uede T (2009) Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol. 182:8015–8025

Kaplony A, Zimmermann DR, Fischer RW, Imhof BA, Odermatt BF, Winterhalter KH, Vaughan L (1991) Tenascin Mr 220, 000 isoform expression correlates with corneal cell migration. Development. 112:605–614

Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 5:749–759

Karjalainen EM, Laitinen A, Sue-Chu M, Altraja A, Bjermer L, Laitinen LA (2000) Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med 161:2086–2091

Kaspar M, Zardi L, Neri D (2006) Fibronectin as target for tumor therapy. Int J Cancer 118:1331–1339

Katz S, Hukkanen M, Lounatmaa K, Rousselle P, Tervo T, Virtanen I (2006) Cooperation of isoforms of laminin-332 and tenascin-CL during early adhesion and spreading of immortalized human corneal epithelial cells. Exp Eye Res 83:1412–1422

Kenji K, Hironori U, Hideya Y, Michinori I, Yasuhiko H, Nobuoki K (2004) Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J. 68:198–203

Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457:102–106

Knaggs HE, Layton AM, Morris C, Wood EJ, Holland DB, Cunliffe WJ (1994) Investigation of the expression of the extracellular matrix glycoproteins tenascin and fibronectin during acne vulgaris. Br J Dermatol 130:576–582

Konstantopoulos K, Thomas SN (2009) Cancer Cells in Transit: The Vascular Interactions of Tumor Cells. Annu Rev Biomed Eng 11:177–202

Koyama Y, Kusubata M, Yoshiki A, Hiraiwa N, Ohashi T, Irie S, Kusakabe M (1998) Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. J Invest Dermatol. 111:930–935

Kucera T, Strilic B, Regener K, Schubert M, Laudet V, Lammert E (2009) Ancestral vascular lumen formation via basal cell surfaces. PLoS ONE 4:e4132

Kuhn C, Mason RJ (1995) Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 147:1759–1769

Kusubata M, Hirota A, Ebihara T, Kuwaba K, Matsubara Y, Sasaki T, Kusakabe M, Tsukada T, Irie S, Koyama Y (1999) Spatiotemporal changes of fibronectin, tenascin-C, fibulin-1, and fibulin-2 in the skin during the development of chronic contact dermatitis. J Invest Dermatol. 113:906–912

Kuznetsova SA, Roberts DD (2004) Functional regulation of T lymphocytes by modulatory extracellular matrix proteins. Int J Biochem Cell Biol 36:1126–1134

Lange K, Kammerer M, Hegi ME, Grotegut S, Dittmann A, Huang W, Fluri E, Yip GW, Gotte M, Ruiz C, Orend G (2007) Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res 67:6163–6173

Lange K, Kammerer M, Saupe F, Hegi ME, Grotegut S, Fluri E, Orend G (2008) Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res 68:6942–6952

Latijnhouwers M, Bergers M, Ponec M, Dijkman H, Andriessen M, Schalkwijk J (1997) Human epidermal keratinocytes are a source of tenascin-C during wound healing. J Invest Dermatol. 108:776–783

Latijnhouwers MA, Bergers M, Van Bergen BH, Spruijt KI, Andriessen MP, Schalkwijk J (1996) Tenascin expression during wound healing in human skin. J Pathol. 178:30–35

Lieber CS, Weiss DG, Paronetto F (2008) Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res 32:1031–1039

Lightner VA, Gumkowski F, Bigner DD, Erickson HP (1989) Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy. J Cell Biol. 108:2483–2493

Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238–11246

Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183

Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC (1998) Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci 39:1135–1142

Loike JD, Cao L, Budhu S, Hoffman S, Silverstein SC (2001) Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins. J Immunol. 166:7534–7542

Lokmic Z, Lammermann T, Sixt M, Cardell S, Hallmann R, Sorokin L (2008) The extracellular matrix of the spleen as a potential organizer of immune cell compartments. Semin Immunol 20:4–13

Lundell A, Olin AI, Morgelin M, al-Karadaghi S, Aspberg A, Logan DT (2004) Structural basis for interactions between tenascins and lectican C-type lectin domains: evidence for a crosslinking role for tenascins. Structure 12:1495–1506

Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 6:297–305

Luster AD, Alon R, von Andrian UH (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 6:1182–1190

Mackie EJ, Halfter W, Liverani D (1988) Induction of tenascin in healing wounds. J Cell Biol. 107:2757–2767

Maier S, Lutz R, Gelman L, Sarasa-Renedo A, Schenk S, Grashoff C, Chiquet M (2008) Tenascin-C induction by cyclic strain requires integrin-linked kinase. Biochim Biophys Acta 1783:1150–1162

Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res. 14:6515–6524

Martin D, Brown-Luedi M, Chiquet-Ehrismann R (2003) Tenascin-C signaling through induction of 14-3-3 tau. J Cell Biol. 160:171–175

Marton LS, Gulcher JR, Stefansson K (1989) Binding of hexabrachions to heparin and DNA. J Biol Chem. 264:13145–13149

Marx J (2008) Cancer biology. All in the stroma: cancer’s Cosa Nostra. Science 320:38–41

Matsuda A, Hirota T, Akahoshi M, Shimizu M, Tamari M, Miyatake A, Takahashi A, Nakashima K, Takahashi N, Obara K, Yuyama N, Doi S, Kamogawa Y, Enomoto T, Ohshima K, Tsunoda T, Miyatake S, Fujita K, Kusakabe M, Izuhara K, Nakamura Y, Hopkin J, Shirakawa T (2005) Coding SNP in tenascin-C Fn-III-D domain associates with adult asthma. Hum Mol Genet 14:2779–2786

Matsuda A, Yoshiki A, Tagawa Y, Matsuda H, Kusakabe M (1999) Corneal wound healing in tenascin knockout mouse. Invest Ophthalmol Vis Sci 40:1071–1080

McClain SA, Simon M, Jones E, Nandi A, Gailit JO, Tonnesen MG, Newman D, Clark RA (1996) Mesenchymal cell activation is the rate-limiting step of granulation tissue induction. Am J Pathol 149:1257–1270

McMahon B, Kwaan HC (2008) The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 36:184–194

Mercado ML, Nur-e-Kamal A, Liu HY, Gross SR, Movahed R, Meiners S (2004) Neurite outgrowth by the alternatively spliced region of human tenascin-C is mediated by neuronal alpha7beta1 integrin. J Neurosci. 24:238–247

Michele M, Faissner A (2009) Tenascin-C stimulates contactin-dependent neurite outgrowth via activation of phospholipase C. Mol Cell Neurosci 41:397–408

Midwood KS, Schwarzbauer JE (2002) Tenascin-C modulates matrix contraction via focal adhesion kinase- and Rho-mediated signaling pathways. Mol Biol Cell 13:3601–3613

Midwood KS, Valenick LV, Hsia HC, Schwarzbauer JE (2004a) Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol Biol Cell 15:5670–5677

Midwood KS, Williams LV, Schwarzbauer JE (2004b) Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 36:1031–1037

Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B (2009) Tenascin-C is an endogenous activator of toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15:774–780

Mighell AJ, Thompson J, Hume WJ, Markham AF, Robinson PA (1997) Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Int J Cancer 72:236–240

Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Korfer R, Klein M, Krahn T, Kruska L, El Banayosy A, Kramer F (2008) Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 27:589–596

Moritz S, Lehmann S, Faissner A, von Holst A (2008) An induction gene trap screen in neural stem cells reveals an instructive function of the niche and identifies the splicing regulator sam68 as a tenascin-C-regulated target gene. Stem Cells. 26:2321–2331

Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M (1991) Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol. 115:1127–1136

Nakahara H, Gabazza EC, Fujimoto H, Nishii Y, D’Alessandro-Gabazza CN, Bruno NE, Takagi T, Hayashi T, Maruyama J, Maruyama K, Imanaka-Yoshida K, Suzuki K, Yoshida T, Adachi Y, Taguchi O (2006) Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 36:3334–3345

Nakao N, Hiraiwa N, Yoshiki A, Ike F, Kusakabe M (1998) Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am J Pathol 152:1237–1245

Nomi M, Miyake H, Sugita Y, Fujisawa M, Soker S (2006) Role of growth factors and endothelial cells in therapeutic angiogenesis and tissue engineering. Curr Stem Cell Res Ther. 1:333–343

Orend G (2005) Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 37:1066–1083

Orend G, Chiquet-Ehrismann R (2000) Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp Cell Res 261:104–110

Orend G, Chiquet-Ehrismann R (2006) Tenascin-C induced signaling in cancer. Cancer Lett 244:143–163

Orend G, Huang W, Olayioye MA, Hynes NE, Chiquet-Ehrismann R (2003) Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene. 22:3917–3926

Paallysaho T, Tervo K, Kivela T, Virtanen I, Tarkkanen A, Tervo T (1993) Cellular fibronectin and tenascin in an orbital nylon prosthesis removed because of infection caused by Staphylococcus aureus. Graefes Arch Clin Exp Ophthalmol 231:61–65

Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231

Paik DC, Fu C, Bhattacharya J, Tilson MD (2004) Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med. 36:524–533

Paivaniemi OE, Maasilta PK, Alho HS, Vainikka TL, Salminen US (2008) Epithelial tenascin predicts obliterative airway disease. J Heart Lung Transplant. 27:400–407

Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A, Mohanakumar T (2005) Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer. 47:17–29

Pas J, Wyszko E, Rolle K, Rychlewski L, Nowak S, Zukiel R, Barciszewski J (2006) Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol 38:1594–1602

Pendas-Franco N, Aguilera O, Pereira F, Gonzalez-Sancho JM, Munoz A (2008) Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res 28:2613–2623

Phillips GR, Krushel LA, Crossin KL (1998) Domains of tenascin involved in glioma migration. J Cell Sci. 111(Pt 8):1095–1104

Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ (1999) The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 81:1311–1317

Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 84:623–630

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273

Prieto AL, Andersson-Fisone C, Crossin KL (1992) Characterization of multiple adhesive and counteradhesive domains in the extracellular matrix protein cytotactin. J Cell Biol. 119:663–678

Prieto AL, Edelman GM, Crossin KL (1993) Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc Natl Acad Sci U S A. 90:10154–10158

Probstmeier R, Pesheva P (1999) Tenascin-C inhibits beta1 integrin-dependent cell adhesion and neurite outgrowth on fibronectin by a disialoganglioside-mediated signaling mechanism. Glycobiology. 9:101–114

Puente Navazo MD, Valmori D, Ruegg C (2001) The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol. 167:6431–6440

Ramos DM, Chen B, Regezi J, Zardi L, Pytela R (1998) Tenascin-C matrix assembly in oral squamous cell carcinoma. Int J Cancer 75:680–687

Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD (2008) A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 10:182–189

Richter P, Tost M, Franz M, Altendorf-Hofmann A, Junker K, Borsi L, Neri D, Kosmehl H, Wunderlich H, Berndt A (2009) B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 135:1351–1358

Riedl S, Tandara A, Reinshagen M, Hinz U, Faissner A, Bodenmuller H, Buhr HJ, Herfarth C, Moller P (2001) Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis 16:285–291

Riley GP, Harrall RL, Cawston TE, Hazleman BL, Mackie EJ (1996) Tenascin-C and human tendon degeneration. Am J Pathol 149:933–943

Riou JF, Shi DL, Chiquet M, Boucaut JC (1990) Exogenous tenascin inhibits mesodermal cell migration during amphibian gastrulation. Dev Biol 137:305–317

Ruegg CR, Chiquet-Ehrismann R, Alkan SS (1989) Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc Natl Acad Sci U S A. 86:7437–7441

Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-Ehrismann R, Orend G (2004) Growth promoting signaling by tenascin-C. Cancer Res 64:7377–7385

Rybak JN, Roesli C, Kaspar M, Villa A, Neri D (2007) The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 67:10948–10957

Sahlberg C, Aukhil I, Thesleff I (2001) Tenascin-C in developing mouse teeth: expression of splice variants and stimulation by TGFbeta and FGF. Eur J Oral Sci 109:114–124

Saito Y, Imazeki H, Miura S, Yoshimura T, Okutsu H, Harada Y, Ohwaki T, Nagao O, Kamiya S, Hayashi R, Kodama H, Handa H, Yoshida T, Fukai F (2007) A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem. 282:34929–34937

Sawada Y, Onoda K, Imanaka-Yoshida K, Maruyama J, Yamamoto K, Yoshida T, Shimpo H (2007) Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res 74:366–376

Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM, Grone HJ (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 115:2223–2233

Schafer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 9:628–638

Schalkwijk J, Steijlen PM, van Vlijmen-Willems IM, Oosterling B, Mackie EJ, Verstraeten AA (1991a) Tenascin expression in human dermis is related to epidermal proliferation. Am J Pathol 139:1143–1150

Schalkwijk J, Van Vlijmen I, Oosterling B, Perret C, Koopman R, Van den Born J, Mackie EJ (1991b) Tenascin expression in hyperproliferative skin diseases. Br J Dermatol 124:13–20

Schenk S, Bruckner-Tuderman L, Chiquet-Ehrismann R (1995) Dermo-epidermal separation is associated with induced tenascin expression in human skin. Br J Dermatol 133:13–22

Schenk S, Chiquet-Ehrismann R, Battegay EJ (1999) The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. Mol Biol Cell 10:2933–2943

Schmidinger G, Hanselmayer G, Pieh S, Lackner B, Kaminski S, Ruhswurm I, Skorpik C (2003) Effect of tenascin and fibronectin on the migration of human corneal fibroblasts. J Cataract Refract Surg. 29:354–360

Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D, Pytela R (1995) The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J Biol Chem. 270:23196–23202

Seiffert M, Beck SC, Schermutzki F, Muller CA, Erickson HP, Klein G (1998) Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. Matrix Biol 17:47–63

Seite S, Colige A, Piquemal-Vivenot P, Montastier C, Fourtanier A, Lapiere C, Nusgens B (2000) A full-UV spectrum absorbing daily use cream protects human skin against biological changes occurring in photoaging. Photodermatol Photoimmunol Photomed 16:147–155

Seyger MM, van Pelt JP, van den Born J, Latijnhouwers MA, de Jong EM (1997) Epicutaneous application of leukotriene B4 induces patterns of tenascin and a heparan sulfate proteoglycan epitope that are typical for psoriatic lesions. Arch Dermatol Res 289:331–336

Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology (Williston Park) 16:217–226 229; discussion 230–2

Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D (2006) Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel. 19:471–478

Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L (1995) Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 270:8650–8654

Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, Miserez AR, Kiss R, Lino MM, Merlo A, Chiquet-Ehrismann R, Boulay JL (2009) Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res 69:458–465

Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275–293

Spring J, Beck K, Chiquet-Ehrismann R (1989) Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments. Cell 59:325–334

Sriramarao P, Bourdon MA (1993) A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices. Nucleic Acids Res 21:163–168

Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456:814–818

Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L, Wells A (2001) Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol. 154:459–468

Talts JF, Wirl G, Dictor M, Muller WJ, Fassler R (1999) Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci. 112:1855–1864

Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T (2005) Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 167:71–80

Tanaka K, Hiraiwa N, Hashimoto H, Yamazaki Y, Kusakabe M (2004) Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer 108:31–40

Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147–152

Taylor HC, Lightner VA, Beyer WF Jr, McCaslin D, Briscoe G, Erickson HP (1989) Biochemical and structural studies of tenascin/hexabrachion proteins. J Cell Biochem. 41:71–90

Tiitta O, Wahlstrom T, Paavonen J, Linnala A, Sharma S, Gould VE, Virtanen I (1992) Enhanced tenascin expression in cervical and vulvar koilocytotic lesions. Am J Pathol 141:907–913

Tran KT, Griffith L, Wells A (2004) Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen. 12:262–268

Tran KT, Lamb P, Deng JS (2005) Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci. 40:11–20

Trebaul A, Chan EK, Midwood KS (2007) Regulation of fibroblast migration by tenascin-C. Biochem Soc Trans 35:695–697

Tremble P, Chiquet-Ehrismann R, Werb Z (1994) The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell 5:439–453

Tsukada B, Terasaki F, Shimomura H, Otsuka K, Otsuka K, Katashima T, Fujita S, Imanaka-Yoshida K, Yoshida T, Hiroe M, Kitaura Y (2009). High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol 40:1015–1022

Tucker RP (1998) Quantitative in situ localization of tenascin-C alternatively spliced transcripts in the avian optic tectum. Mol Vis. 4:18

Tucker RP (2001) Abnormal neural crest cell migration after the in vivo knockdown of tenascin-C expression with morpholino antisense oligonucleotides. Dev Dyn 222:115–119

Tucker RP, Chiquet-Ehrismann R (2009) The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 1793:888–892

van der Vleuten CJ, Snijders CG, de Jong EM, van de Kerkhof PC (1996) Effects of calcipotriol and clobetasol-17-propionate on UVB-irradiated human skin: an immunohistochemical study. Skin Pharmacol 9:355–365

Van Eyken P, Sciot R, Desmet VJ (1990) Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohistochemical study. J Hepatol. 11:43–52

Villani ME, Morgun B, Brunetti P, Marusic C, Lombardi R, Pisoni I, Bacci C, Desiderio A, Benvenuto E, Donini M (2009) Plant pharming of a full-sized, tumour-targeting antibody using different expression strategies. Plant Biotechnol J 7:59–72

Vollmer G (1997) Biologic and oncologic implications of tenascin-C/hexabrachion proteins. Crit Rev Oncol Hematol 25:187–210

von Lukowicz T, Silacci M, Wyss MT, Trachsel E, Lohmann C, Buck A, Luscher TF, Neri D, Matter CM (2007) Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med. 48:582–587

Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE (2005) Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65:1294–1305

Wallner K, Li C, Shah PK, Wu KJ, Schwartz SM, Sharifi BG (2004) EGF-Like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 24:1416–1421

Watanabe K, Takahashi H, Habu Y, Kamiya-Kubushiro N, Kamiya S, Nakamura H, Yajima H, Ishii T, Katayama T, Miyazaki K, Fukai F (2000) Interaction with heparin and matrix metalloproteinase 2 cleavage expose a cryptic anti-adhesive site of fibronectin. Biochemistry. 39:7138–7144

Wenk MB, Midwood KS, Schwarzbauer JE (2000) Tenascin-C suppresses Rho activation [see comments]. J Cell Biol. 150:913–920

Whitby DJ, Longaker MT, Harrison MR, Adzick NS, Ferguson MW (1991) Rapid epithelialisation of fetal wounds is associated with the early deposition of tenascin. J Cell Sci. 99(Pt 3):583–586

Williams SA, Schwarzbauer JE (2009) A shared mechanism of adhesion modulation for tenascin-C and fibulin-1. Mol Biol Cell 20:1141–1149

Woodside DG, Wooten DK, McIntyre BW (1998) Adenosine diphosphate (ADP)-ribosylation of the guanosine triphosphatase (GTPase) rho in resting peripheral blood human T lymphocytes results in pseudopodial extension and the inhibition of T cell activation. J Exp Med. 188:1211–1221

Yamada S, Ichida T, Matsuda Y, Miyazaki Y, Hatano T, Hata K, Asakura H, Hirota N, Geerts A, Wisse E (1992) Tenascin expression in human chronic liver disease and in hepatocellular carcinoma. Liver. 12:10–16

Yamamoto K, Onoda K, Sawada Y, Fujinaga K, Imanaka-Yoshida K, Shimpo H, Yoshida T, Yada I (2005) Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res 65:737–742

Yamamoto K, Onoda K, Sawada Y, Fujinaga K, Imanaka-Yoshida K, Yoshida T, Shimpo H (2007) Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg. 13:322–330

Yokosaki Y, Monis H, Chen J, Sheppard D (1996) Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin Roles of the beta subunit extracellular and cytoplasmic domains. J Biol Chem. 271:24144–24150

Yokoyama K, Erickson HP, Ikeda Y, Takada Y (2000) Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3. J Biol Chem. 275:16891–16898

Zagzag D, Capo V (2002) Angiogenesis in the central nervous system: a role for vascular endothelial growth factor/vascular permeability factor and tenascin-C. Common molecular effectors in cerebral neoplastic and non-neoplastic “angiogenic diseases”. Histol Histopathol 17:301–321

Zhao Y, Young SL (1995) TGF-beta regulates expression of tenascin alternative-splicing isoforms in fetal rat lung. Am J Physiol 268:L173–L180

Zukiel R, Nowak S, Wyszko E, Rolle K, Gawronska I, Barciszewska MZ, Barciszewski J (2006) Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther. 5:1002–1007

The role of tenascin-C in tissue injury and tumorigenesis

Research Article

References